Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25826615 | 0.85 | SMN1; SMN2 (0.38) | FFAR1ROCK2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25826612 | 0.84 | FFAR1 (0.37) | FFAR1CA1CA2POLB | |
| SCHEMBL25826624 | 0.80 | MEN1 (0.39) | ROCK2MEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL27421364 | 0.79 | L3MBTL1 (0.40) | FFAR1ROCK2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25827944 | 0.78 | HRH3 (0.36) | ROCK2SMN1; SMN2CA1ELANE | |
| SCHEMBL27102419 | 0.75 | MEN1 (0.42) | ROCK2MEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL15242395 | 0.73 | ALDH1A1 (0.43) | MEN1KMT2AL3MBTL1CA1CA2 | |
| SCHEMBL21120303 | 0.73 | KMT2A (0.43) | ROCK2MEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL27305897 | 0.71 | ELANE (0.52) | MEN1KMT2ASMN1; SMN2L3MBTL1ELANE | |
| SCHEMBL18792766 | 0.70 | ELANE (0.46) | ROCK2MEN1KMT2ASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207412-A1 | DIELS-ALDER CONJUGATION METHODS | REGENERON PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-11701427-B2 | Diels-alder conjugation methods | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207412-A1 | DIELS-ALDER CONJUGATION METHODS | GLUL, TGM2, GLS | FFAR1 3820/4885ROCK2 3065/4885MEN1 613/4885 |
| US-11701427-B2 | Diels-alder conjugation methods | GLUL, TGM2, GLS | FFAR1 3820/4885ROCK2 3065/4885MEN1 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.